new
   What is Canagliflozin Hydrochloride (Canaglu)?
502
Nov 24, 2025

Canagliflozin Hydrochloride (Canaglu) is a novel sodium-glucose cotransporter 2 (SGLT2) inhibitor developed by Bayer, primarily indicated for the treatment of type 2 diabetes mellitus. As a key member of oral hypoglycemic agents, its unique mechanism of action and clinical advantages provide a new option for diabetes management.

What is Canagliflozin Hydrochloride (Canaglu)?

Drug Classification and Mechanism of Action

Canagliflozin Hydrochloride belongs to the class of SGLT2 inhibitors. It selectively inhibits SGLT2 in the proximal convoluted tubule of the kidneys, reducing glucose reabsorption and promoting urinary glucose excretion, thereby lowering blood glucose levels.

Main Indications

Primarily used to improve glycemic control in adult patients with type 2 diabetes mellitus, either as monotherapy or in combination with other oral hypoglycemic agents.

In certain cases, it may also be used in combination with insulin to optimize glycemic management outcomes.

Specifications and Characteristics of Canagliflozin Hydrochloride (Canaglu)

Dosage Form and Strengths

Canagliflozin Hydrochloride is available as oral tablets, with common strengths including 100 mg and 300 mg.

The tablets are film-coated, presenting as round or oval in shape. Specific shape and color may vary by manufacturer.

Physical Characteristics Description

The tablet surface is usually imprinted with dosage markings for easy identification and differentiation.

100 mg tablets are mostly white or light-colored, while 300 mg tablets may be dark yellow or orange.

The tablets are hard in texture, odorless, and maintain stable physical properties under normal storage conditions.

Storage Methods for Canagliflozin Hydrochloride (Canaglu)

Storage Environment Requirements

Unopened medications should be stored in their original packaging at a temperature of 20-25°C (68-77°F). Short-term transportation is permitted within a temperature range of 15-30°C (59-86°F).

Avoid direct sunlight and humid environments.

Post-Opening Management

After opening, keep the bottle tightly capped and store in a dry place.

It is recommended to mark the opening date on the bottle. Generally, the medication should be used within 6 months after opening; refer to the package insert for the exact shelf life.

Special Precautions

Do not store the medication in high-humidity areas such as bathrooms or kitchens.

Ensure the medication is placed out of the reach of children to prevent accidental ingestion.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
RELATED ARTICLES
Dosage and Administration, Recommended Dose of Elacestrant (Orserdu)

Elacestrant (Orserdu) is a selective estrogen receptor degrader (SERD), which provides an important treatment option...

Friday, December 19th, 2025, 11:49
What Are the Indications for Elacestrant (Orserdu)?

Elacestrant (Orserdu) is a novel endocrine therapy agent that demonstrates significant value in the treatment of...

Friday, December 19th, 2025, 11:40
What Are the Purchase Channels for Elacestrant (Orserdu)?

With the advancement of medical technology, elacestrant (Orserdu), a targeted drug for breast cancer with specific...

Friday, December 19th, 2025, 11:38
Adverse Reactions of Capmatinib (Tabrecta)

Capmatinib (Tabrecta) is a highly selective MET inhibitor indicated for the treatment of patients with advanced...

Friday, December 19th, 2025, 11:35
RELATED MEDICATIONS
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved